Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
05
06
2021
pubmed:
4
7
2021
medline:
4
7
2021
entrez:
3
7
2021
Statut:
ppublish
Résumé
Access and funding for newly approved treatments for non-small cell lung cancer (NSCLC) are often dependent on Health Technology Assessment (HTA) involving cost-effectiveness analysis. Whilst methods used by HTA agencies share many similarities, final decisions may differ. This may be the result, not just of price considerations, but also of variation in value judgements by different agencies. The aim of this study was to review international HTA evaluations to identify determinants of value and access for NSCLC treatments. A targeted review and analysis was undertaken of published HTAs for NSCLC across HTA agencies in six countries (Australia, Canada, England, France, Ireland and Scotland). Analysis of extracted data consisted of three stages: descriptive analysis, bivariate analysis and multivariable analysis. The analysis included 163 HTAs that assessed oncological treatments for NSCLC from 2003 to 2019. The majority of HTA decisions (67.5%) were positive. However, some evidence of heterogeneity in HTA decisions and the factors informing them were identified. The most influential factors included in the multivariate model related to the HTA agency conducting the appraisal, the year of market authorisation, treatment type and the line of treatment. Heterogenous decision-making frameworks can present a challenge to developing HTA submissions. This research contributes to understanding decision-making factors and why countries make different decisions.
Identifiants
pubmed: 34216002
doi: 10.1007/s41669-021-00279-2
pii: 10.1007/s41669-021-00279-2
pmc: PMC8611140
doi:
Types de publication
Journal Article
Langues
eng
Pagination
701-713Informations de copyright
© 2021. The Author(s).
Références
Onco Targets Ther. 2017 Aug 29;10:4295-4303
pubmed: 28919778
Eur J Health Econ. 2017 Jul;18(6):715-730
pubmed: 27538758
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
Int J Technol Assess Health Care. 2018 Jan;34(3):224-240
pubmed: 29987996
Value Health. 2018 Feb;21(2):161-165
pubmed: 29477394
Health Policy. 2006 Aug;77(3):352-67
pubmed: 16213624
Oncology. 2019;97(4):228-235
pubmed: 31216560
Health Policy. 2012 Dec;108(2-3):167-77
pubmed: 23088802
Health Policy. 2019 Feb;123(2):130-139
pubmed: 30477736
J Clin Oncol. 2008 Oct 1;26(28):4617-25
pubmed: 18678835
Value Health. 2015 Mar;18(2):284-91
pubmed: 25773564
Medicine (Baltimore). 2018 Aug;97(33):e11936
pubmed: 30113497
Pharmacoeconomics. 2016 Sep;34(9):925-37
pubmed: 27034245
Value Health. 2020 Mar;23(3):319-327
pubmed: 32197727
Value Health. 2017 Mar;20(3):320-328
pubmed: 28292476
Value Health. 2021 Apr;24(4):505-512
pubmed: 33840428
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):251-261
pubmed: 30696372
BMC Cancer. 2019 Mar 8;19(1):214
pubmed: 30849964
Br J Clin Pharmacol. 2020 Jan;86(1):93-105
pubmed: 31656055
Value Health. 2017 Jan;20(1):67-76
pubmed: 28212972
Front Pharmacol. 2017 Jun 30;8:384
pubmed: 28713265
Value Health. 2020 Jan;23(1):10-16
pubmed: 31952664
Health Econ Policy Law. 2014 Apr;9(2):119-41
pubmed: 23688554
Health Econ. 2015 Oct;24(10):1256-1271
pubmed: 25251336
Int J Technol Assess Health Care. 2013 Oct;29(4):456-65
pubmed: 24290340
Clinicoecon Outcomes Res. 2013;5:69-85
pubmed: 23403392
Health Econ. 2004 May;13(5):437-52
pubmed: 15127424
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003463